within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AA58_EfgartigimodAlfa;

model EfgartigimodAlfa
  extends Pharmacolibrary.Drugs.ATC.L.L04AA58;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L04AA58</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Efgartigimod alfa is a human IgG1-derived Fc fragment designed to bind to the neonatal Fc receptor (FcRn), resulting in a reduction of circulating IgG levels. It is approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor antibody positive.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters as reported in healthy adult subjects after intravenous infusion.</p><h4>References</h4><ol><li><p>Jing, S, et al., &amp; Pu, X (2024). Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese Participants. <i>Drugs in R&amp;D</i> 24(4) 505â€“515. DOI:<a href=\"https://doi.org/10.1007/s40268-024-00490-6\">10.1007/s40268-024-00490-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39368043/\">https://pubmed.ncbi.nlm.nih.gov/39368043</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end EfgartigimodAlfa;
